[SCHEDULE 13G/A] Precision BioSciences, Inc. SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

PRECISION BIOSCIENCES INC

(Name of Issuer)

Common stock, par value $0.000005 per share

(Title of Class of Securities)

74019P207

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

Novartis Pharma AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 413,581.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 413,581.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

413,581.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.7 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

Novartis AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 413,581.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 413,581.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

413,581.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.7 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PRECISION BIOSCIENCES INC
(b)	Address of issuer's principal executive offices: 302 EAST PETTIGREW STREET SUITE A-100, DURHAM, NC, 27701
Item 2.
(a)	Name of person filing: This statement is filed on behalf of the following persons with respect to the shares of Common Stock of the Issuer: (i) Novartis Pharma AG, a Swiss corporation ("Novartis Pharma"), with respect to shares held by it; and (ii) Novartis AG, a Swiss corporation ("Novartis"), as the publicly-owned parent of Novartis Pharma, with respect to the shares held by Novartis Pharma. The foregoing persons are hereinafter referred to collectively as the "Reporting Persons."
(b)	Address or principal business office or, if none, residence: The address of the principal business offices of the Reporting Persons is Lichtstrasse 35, CH-4056 Basel, Switzerland.
(c)	Citizenship: Novartis Pharma is a corporation organized under the laws of Switzerland and is a direct wholly-owned subsidiary of Novartis. Novartis is a corporation organized under the laws of Switzerland and is the publicly-owned parent of Novartis Pharma.
(d)	Title of class of securities: Common stock, par value $0.000005 per share
(e)	CUSIP No.: 74019P207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Items 4(a)-(c) with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 11,088,234 outstanding shares of Common Stock, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.
(b)	Percent of class:
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote:
	(ii) Shared power to vote or to direct the vote:
	(iii) Sole power to dispose or to direct the disposition of:
	(iv) Shared power to dispose or to direct the disposition of:
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Novartis Pharma AG

Signature:	/s/ Christian Rehm
Name/Title:	Christian Rehm / Authorised Signatory
Date:	08/05/2025

Signature:	/s/ Lukas Foertsch
Name/Title:	Lukas Foertsch / Authorised Signatory
Date:	08/05/2025

Novartis AG

Signature:	/s/ Christian Rehm
Name/Title:	Christian Rehm / Authorised Signatory
Date:	08/05/2025

Signature:	/s/ Daniel Weiss
Name/Title:	Daniel Weiss / Authorised Signatory
Date:	08/05/2025

Exhibit Information

Exhibit 1 - Evidence of Signatory Authority